KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.

Heinz Josef Lenz, Edward Chu, Axel Grothey

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

As with many malignancies, cytogenetic information has become increasingly important to the diagnosis and proper treatment of colorectal cancer. In particular, several recent studies have confirmed that KRAS is not only one of the most commonly mutated genes in colorectal cancer, but also essential to treatment decision-making. Several key studies have demonstrated that patients with mutant KRAS do not respond to treatment with epidermal growth factor inhibitors. This finding has several implications for clinicians who treat patients with metastatic colorectal cancer. The following monograph includes discussions on the key issues surrounding the integration of recent data on KRAS status into the care of patients with this disease.

Original languageEnglish (US)
Pages (from-to)1-13, 14-16
JournalClinical advances in hematology & oncology : H&O
Volume6
Issue number12
StatePublished - Dec 2008

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.'. Together they form a unique fingerprint.

  • Cite this